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Previewsand the response to new therapies in lym-
phomas deserves further exploration.
Additional mechanisms, such as muta-
tions in BTK or in other targets of the
new drugs, may also emerge and confer
resistance in MCL. The preclinical results
presented by Rahal et al. (2013) provide
critical insights into understanding the
mechanisms of response to new drugs
and suggest innovative therapeutic
strategies for tumors refractory to BCR
signaling inhibitors. The study also high-
lights the increasing clinical interest of
sequencing tumors to guide the selection
of new therapies in lymphoid neoplasms.
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Thalidomide and related drugs are key drugs for the treatment of multiple myeloma (MM). These agents
bind to cereblon, a component of a ubiquitin ligase complex, altering the specificity of the complex to induce
the ubiquitylation and degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors essential for
MM growth.The story of the use of thalidomide and
related compounds in the treatment of
multiple myeloma (MM) represents a
remarkable case of bedside to bench
research. Thalidomide may have first
been discovered during World War II as
a potential antidote to nerve gas and
was developed as a sedative used for
morning sickness in the 1950s. This
culminated in a great medical tragedy
because of the extraordinary teratogenic
effects on limb development. The drug
was abandoned but was later explored
for the treatment of leprosy ulcers, HIV/
AIDS, and autoimmune diseases. Theseanti-inflammatory effects were linked to
inhibition of tumor necrosis factor secre-
tion, providing an early indication that
thalidomide functioned as an immune
modulatory drug (IMiD). Dr. Judah Folk-
man and colleagues subsequently found
that thalidomide inhibited tumor associ-
ated angiogenesis. Folkman’s advice
to a patient to try thalidomide in MM
(http://www.nytimes.com/1999/11/18/us/
thalidomide-found-to-slow-a-bone-cancer.
html) led to a seminal study showing
a 32% response rate of MM patients to
a single agent thalidomide treatment,
including complete responses in severalpatients refractory to all prior therapies
(Singhal et al., 1999). Thalidomide in
combination with dexamethasone as an
initial therapy yields response rates of
>60%, while lenalidomide, a chemically
similar IMiD with fewer constitutional
side effects, plus dexamethasone yields
responses in 80% of patients. The use
of these IMiDs along with the protea-
some inhibitor bortezomib has extended
the median survival of MM patients to
greater than 7 years. This remarkable
progress occurred in the absence of
clear molecular and biological mecha-
nisms of action of thalidomide,25, January 13, 2014 ª2014 Elsevier Inc. 9
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Figure 1. Mechanism of Action of Thalidomide in MM
(A) In the absence of an IMiD, CRBN-directed ubiquitin ligase activity is directed toward CRBN itself and possibly other as-yet-undefined targets that are tagged
for proteasome-mediated degradation. IKZF1 and IKZF3 are stabilized to induce the expression of IRF4, which in turn can induceMYC expression and regulate
the expression of other unidentified target genes. IKZF1/3 also repress expression of IL2 in T cells.
(B) Binding of a thalidomide analog to CRBN modulates its substrate recognition, preventing auto-ubiquitylation while augmenting the ubiquitylation and
degradation of IKZF1/3 and potentially other substrates. Loss of IKZF1/3 leads to reduced IRF4 and MYC expression in MM cells and to loss of their viability,
whereas it stimulates IL-2 secretion in T cells to enhance immune function. Furthermore, the shift in CRBN targeting might also result in stabilization
of other targets that are ubiqutylated in the absence of thalidomide analogs, for example, restoring levels of haploinsufficient proteins in myelodysplasia
with del(5q). In addition, stabilization of CRBN targets following IMiD binding was also proposed to result in decreased expression of FGF8, resulting in limb
malformation.
Cancer Cell
Previewslenalidomide, and the more recently
introduced pomalidomide.
Initial mechanistic studies showed that
thalidomide and other IMiD drugs had a
direct effect on the proliferation of MM
cell lines and patients specimens, which
was associated with upregulation of p21
and induction of apoptosis (Hideshima
et al., 2000). Potential immunemodulating
effects included enhanced T cell secre-
tion of interleukin-2 (IL-2) and enhanced
killing of MM cells in vitro by natural killer
cells (Davies et al., 2001). Other studies
suggested that IMiDs affected the bone
marrow microenvironment and altered
the epigenetic state of MM cells. These
agents also have clinical activity in
myelodysplasia associated with del(5q).
In particular, lenalidomide, but not thalid-
omide, suppressed the enzymatic activity
of the CDC25 phosphatases encoded by
the 5q region and altered the intracellular
trafficking of this molecule. Altered phos-10 Cancer Cell 25, January 13, 2014 ª2014 Ephatase activity led to the altered stability
of CDC25 downstream targets, including
MDM2 and, indirectly, p53 (Wei et al.,
2009). Although potentially relevant, these
experiments did not reveal a common
molecular mechanism for the antitumor
effects of IMiDs.
A breakthrough came from a proteomic
experiment in which a thalidomide
derivative was used to purify interacting
proteins and identified cereblon (CRBN)
and DDB1 (Ito et al., 2010). CRBN and
DDB1 were components of an E3 ubiqui-
tin ligase complex that also contained
CUL4 and Roc1. These initial experiments
only identified CRBN itself as a substrate;
the binding of thalidomide to CRBN
inhibited autoubiquitylation of CRBN.
Importantly, CBRN was shown to be the
target responsible for teratogenesis in
zebrafish, because thalidomide treatment
and morphilino-mediated knockdown of
CRBN yielded the same developmentallsevier Inc.deformities. Conversely, a mutant form
of CRBN that failed to bind thalidomide
rescued the teratogenic effects of the
drug. These results led to a working
hypothesis that thalidomide and related
drugs inhibited the ubiquitin ligase acti-
vity of a critical complex, resulting in
decreased expression of FGF8, a factor
critical for limb development, and leading
to deformity (Figure 1).
These results were rapidly translated
to studies in MM. Like thalidomide,
lenalidomide and pomalidomide inhibited
autoubiquitylation of CRBN (Lopez-Gi-
rona et al., 2012). Knockdown of CRBN
in MM cells decreased cell viability, but
cells that survived decreased CRBN
levels became resistant to the antipro-
liferative effects of lenalidomide and
pomalidomide (Zhu et al., 2011) while
overexpression of CRBN augmented
sensitivity of MM cells to these agents
(Lopez-Girona et al., 2012). Furthermore
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acquired a deletion of the CRBN gene
and MM that developed lenalidomide
resistance demonstrated decreased
CRBN levels (Zhu et al., 2011), whereas
elevated CRBN levels were associated
with better clinical response to IMiDs.
IMiD treatment of MM cells was associ-
ated with decreased expression of IRF4,
a transcription factor previously shown
to be essential for MM cell proliferation.
IRF4 stimulates the expression of MYC,
which is normally downregulated in the
mature plasma cells, but is pervasively
upregulated in MM. A potential mecha-
nism of action of the IMiDs in modulating
levels of critical transcription factors
could thus be postulated (Figure 1).
Furthermore, the effect of IMiDs on
CRBN also began to explain the ability
of these drugs to alter T cell secretion of
IL-2 and tumor necrosis factor-a (Lopez-
Girona et al., 2012). Thus, these results
began to explain the pleotropic effects of
IMiDs on the immune system and MM
cells through their ability to bind and
target CRBN. However, simple inhibition
of the complex seemed unlikely to be
the explanation, because loss of CRBN
led to IMiD insensitivity in MM, whereas
increased expression of CUL4 in prostate
cells increased thalidomide cytotoxicity
(Ren et al., 2012).
Using distinct but complementary pro-
teomic techniques and systems, three
groups simultaneously reported recently
that IMiDs induced the CRBN-dependent
proteasomal degradation of IKZF1
(Ikaros) and IKZF3 (Aiolos) (Gandhi et al.,
2013; Kro¨nke et al., 2013; Lu et al.,
2013). IKZF1, a zinc finger transcription
factor initially discovered as a regulator
of the T cell receptor, is required for
proper hematopoiesis, particularly lym-
phocyte development and plasma cell
maturation. Loss of function mutations of
IKZF1 and IKZF3 are associated with
acute lymphoblastic leukemia, consistent
with a tumor suppressor function. How-ever, as shown by these papers, IZKF1
and IKZF3 expression is required for the
viability of many MM cell lines. IKZF1
bound and activated the IRF4 promoter,
and loss of IKZF1 led to decreased IRF4
and hence MYC expression; however,
lenalidomide could also inhibit MM cell
lines with high basal levels of IRF4 un-
changed by drug treatment, suggesting
that other IKZF1/3 targets can play a
role in the therapeutic response. IZKF1/3
are known repressors of the IL2 promoter,
and their degradation in response to
IMiDs explains enhanced T cell IL-2
production. Hence, many of the cell
autonomous and immunostimulatory
effects of IMiDs can be explained by
a unified mechanism: IMiDs re-target
ligase activity toward IKZF1/3 in a
change-of-function effect (Figure 1).
Although these works represent an
enormous step forward, some questions
clearly remain. Given the therapeutic
effects of IMiDs in myelodysplasia and
preclinical effects in prostate cancer, it
is possible that the CRBN complex has
distinct sets of targets in different cell
types. Kro¨nke et al. (2013) found several
additional MM derived proteins that
bound to CRBN only in the presence
of lenalidomide, whereas other proteins
were consistently released from lenalido-
mide treatment. Hence, other proteins
polyubiquitylated and degraded, mono-
ubiqutylated and compartmentalized or
sequestered by the CRBN complex, or
differentially released and stabilized by
IMiDs may contribute to therapeutic
response. The technologies utilized by
these groups have deeper implications
and suggest that other small molecules
could be developed to alter the speci-
ficity of ubiquitylation complexes with
the aim of inducing the specific degrada-
tion of previously ‘‘undruggable’’ onco-
proteins such as Ras and Myc. What
began with a series of serendipitous
events could lead to a new era of rational
therapy.Cancer Cell 2ACKNOWLEDGMENTS
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